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Papillomavirus E2 is a sequence-specific DNA binding protein that regulates transcription and replication
of the viral genome. The transcriptional activities of E2 are typically evaluated by transient transfection of
nonreplicating E2-dependent reporters. We sought to address whether E2 activates transcription in an epi-
somal context and its potential interaction with the chromatin remodeling proteins. Using an Epstein-Barr
virus-based episomal reporter, we demonstrate that E2 stimulates transcription from an E2-dependent pro-
moter in a chromatin context. This activation is enhanced by the presence of proteins associated with SWI/SNF
complexes, which are ATP-dependent chromatin remodeling enzymes. We show that exogenous expression of
the Brm ATPase enhances E2 activity in SWI/SNF-deficient cell lines and that the amino-terminal transacti-
vation domain of E2 mediates association with the Brm complex in vivo. Using chromatin immunoprecipitation
assays, we demonstrate that Brm enhances promoter occupancy by E2 in an episomal context. Our results
demonstrate that E2 activates transcription from an episomal reporter system and reveal a novel property of
E2 in collaborating with the Brm chromatin remodeling complex in enhancing transcriptional activation.
The double-stranded, closed circular DNA genomes of pap-
illomaviruses naturally replicate as episomes that are associ-
ated with nucleosomal histone proteins (19). In eukaryotes, the
packaging of DNA into nucleosomes and subsequent higher-
order chromatin structures poses an obstacle to nuclear pro-
cesses such as transcription, replication, and recombination
during DNA repair. Transcription factors and other proteins
gain access to nucleosome-bound DNA by using ATP-depen-
dent chromatin modifying and remodeling enzymes. The first
proteins implicated in chromatin remodeling were identified in
yeast by characterization of defects in mating-type switching
(SWI) and sucrose fermentation (SNF [for “sucrose nonfer-
menting”]) (5, 56, 75). The 2-MDa yeast SWI/SNF complex
consists of 11 subunits, with functional homologues found in
flies and mammals (59–61, 72, 82). Brahma (Brm), the regu-
lator of Drosophila homeotic genes, was the first SWI/SNF
relative to be discovered in higher eukaryotes (77). Humans
have at least two genes that are closely related to Brm: hBrm,
also known as hSNF2, and Brm-related gene 1 (Brg1), also
known as hSNF2 (9, 35, 54). These SWI/SNF ATPase sub-
units alone are sufficient for chromatin remodeling activity in
vitro (62). Other subunits are thought to be required for stable
complex assembly and/or targeting of transcription complexes
to the promoter in vivo (55).
The E2 protein has a modular structure with a conserved
N-terminal transactivation domain (TAD) of approximately
220 amino acids that serves as a platform for assembly of
cellular transcription factors, including TBP, TFIIB, Gps2
(AMF1), and Brd4 (3, 7, 31, 58, 64, 69, 74, 89). The C-terminal
100 amino acids form the DNA binding and dimerization do-
main (DBD) (52, 63). The intervening nonconserved region is
proposed to act as a “hinge” that separates the functional
domains of the E2 protein.
Bovine papillomavirus type 1 (BPV1) E2 binds to the pal-
indromic sequence ACCG(N4)CGGT (1), and human papil-
lomavirus (HPV) E2 binds variations on this motif. The long
control region (LCR) includes E2 binding motifs and cis ele-
ments for cellular factors that regulate the early viral promot-
ers in a complex manner (24). These E2 binding sequences
exhibit E2-dependent enhancer activity when present in two or
more copies placed either upstream or downstream of a het-
erologous promoter (27, 73). E2 also activates transcription
from E2-dependent promoters on replicating plasmids in Sac-
charomyces cerevisiae (39, 53). Because the E2 protein regu-
lates viral transcription and replication, we hypothesized that it
would interact with SWI/SNF complexes to overcome nucleo-
some repression.
BPV1 proteins are expressed and its genome is maintained
as stable episomes in cultured murine C127 and NIH 3T3 cells.
HPV genomes replicate in some epithelial cell-derived cell
lines and in primary human keratinocytes but are less stable
than the BPV genome in cultured mouse cell lines. HPVs
are biologically and phylogenetically differentiated into two
groups: “low-risk” types, which cause benign warts and rarely
cancer, and “high-risk” types such as HPV-16 and HPV-18,
which are associated with the development of cervical and
other epithelial malignancies. BPV1 contains 17 E2 binding
motifs present primarily within the LCR (44), while HPV-16
and HPV-18 contain four copies of the E2 binding sequences
in their LCR (16, 51). During the early stages of infection, it is
thought that the high-risk HPV E2 protein represses transcrip-
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tion of the viral E6 and E7 genes by binding to sites situated
adjacent to the early promoter and TBP binding site. It was
proposed that E2 represses this promoter by interfering with
recruitment of the TFIID complex required for initiation of
transcription (13–15, 28, 78). This model was supported by the
report that introduction of E2 into HPV-induced cervical can-
cer cell lines led to activation of p53 and pRb (25), which are
otherwise inactivated by E6 and E7, respectively (20). A trun-
cated BPV E2 repressor (E2R) that initiates from a promoter
embedded within the E2 open reading frame expresses the
DBD but excludes a functional TAD and thus can act as a
transcriptional repressor, although it does not suppress E6 and
E7 expression in HeLa cells (26). Despite repressor functions,
BPV and HPV E2 proteins, including those of HPV-16 and
HPV-18, are potent transcriptional activators of artificial con-
structs with E2 binding sites inserted into a promoter. These
activator and repressor functions may maintain viral ho-
meostasis by regulation of viral gene expression (79). None-
theless, the physiologic roles of BPV and HPV E2 transcrip-
tional activation and repression in early infection are not well
understood.
It was recently reported that HPV E2 represses transcription
from integrated copies of the HPV-16 LCR but has no effect
on transcription from episomal HPV-16 genomes in W12-de-
rived cell lines (2). Therefore, to study the transcriptional ac-
tivation function of E2 in an episomal model, we used a het-
erologous EBV-based episomal reporter system containing E2
binding sites fused to the simian virus 40 (SV40) minimal
promoter. We show that E2 activates transcription in an epi-
somal context and that this activation is enhanced by its inter-
action with the Brm-containing SWI/SNF chromatin remodel-
ing complex.
MATERIALS AND METHODS
C33A, SW13, HeLa, and NIH 3T3 cells were cultured in Dulbecco modified
eagle medium (Gibco) containing 10% bovine calf serum with penicillin and
streptomycin. Flag-K804R Brm was cloned into pCG, transfected into SW13
cells, and selected by cotransfection with pBabe-puro, and a stable expression
line was generated. FuGene 6 (Roche) was used for transfections at a ratio of 3
l to 1 g of DNA. Lipofectamine 2000 was used according to the manufactur-
er’s instructions to transfect Brm and E2 plasmids. After 24 h, cells were washed
in phosphate-buffered saline and lysed with 1 luciferase reporter lysis buffer
(Promega). Lysates were assayed for luciferase activity with the Luminol sub-
strate (Promega), and relative light units were normalized to 20 g of protein.
The reporter plasmid containing four E2 binding sites fused to the SV40
minimal promoter was released from construct pGL2 and cloned into pREP4-
Luc (K. Zhao, NIH). Flag-tagged human Brm with a Kozak sequence inserted
upstream of the coding region was cloned into pCI-Neo (Promega). For coim-
munoprecipitation experiments, cells were extracted with lysis buffer (50 mM
Tris [pH 8.0], 100 mM NaCl, 20 mM NaF, 50 mM KH2PO4, 1% Triton X-100,
10% glycerol, and 0.1 mM dithiothreitol [DTT]) containing protease inhibitor
cocktail. Lysates were sonicated, clarified, and resuspended in binding buffer (50
mM Tris-HCl [pH 8.0], 100 mM KCl, 0.1 mM EDTA, 0.2% NP-40, 2.5% glyc-
erol, and 1 mM DTT). Brm (BD Biosciences), Flag M2 beads (Sigma), and E2
antibodies (58) were captured with protein A/G Sepharose. The beads were
washed with wash buffer (100 mM Tris-HCl [pH 8.0], 100 mM NaCl, 0.5%
NP-40), and bound proteins were resolved by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene diflu-
oride membranes (PALL), which were probed with the appropriate antibodies
and developed with a Pierce chemiluminescence detection kit.
For chromatin immunoprecipitation (ChIP) assays, formaldehyde was added
to the cell medium at a final concentration of 1% at 24 h posttransfection.
Reactions were stopped with 125 mM glycine. After washes with phosphate-
buffered saline, cells were sonicated. Chromatin extract containing 0.1% SDS,
1% Triton X-100, 0.1% sodium deoxycholate, 140 mM NaCl, and 10 mM Tris
(pH 7.4) was incubated with the appropriate antibodies and protein G Sepha-
rose. The beads were washed with buffer containing 0.1% SDS, 1% Triton X-100,
0.1% sodium deoxycholate, 140 mM NaCl, and 10 mM Tris (pH 7.4). Following
a low-salt wash, beads were washed with high-salt buffer containing 0.1% SDS,
1% Triton X-100, 0.1% sodium deoxycholate, 300 mM NaCl, and 10 mM Tris
(pH 7.4). The beads were rinsed with Tris (pH 8)-EDTA and suspended in
elution/de-cross-linking buffer containing 100 mM NaHCO3,1% SDS, and 300
mM NaCl at 65°C for 4 h. Eluted DNA was extracted with phenol-chloroform
isoamyl alcohol mix and was ethanol precipitated in the presence of 10 g of
glycogen. DNA samples were subjected to PCR amplification followed by aga-
rose gel electrophoresis.
RESULTS
E2 activates transcription from an episomal reporter. To
address whether E2 activates transcription from a chromatin
template in vivo, we constructed episomal and conventional
nonreplicating (pGL2) reporters containing four high-affinity
E2 binding sites upstream of a minimal SV40 promoter. The
EBV-based episomal reporter system contains the EBV origin
of replication and the EBNA1 coding region and has been used
to address the chromatin remodeling activity of several tran-
scription factors (17, 29, 46, 48, 84, 87). Synthetic E2 binding
sites along with the SV40 minimal promoter were inserted
upstream of the luciferase gene. The nonreplicating reporter
does not contain a mammalian origin of replication, and reg-
ularly spaced nucleosomes do not assemble on this template.
These reporter constructs were cotransfected into C33A,
SW13, HeLa, and NIH 3T3 cells in the presence or absence of
BPV1 E2 or HPV-16 E2 expression plasmids. C33A and SW13
cells are deficient for Brg1/Brm, while HeLa and NIH 3T3 cells
express relatively high levels of Brg1 and Brm. In C33A cells,
there was robust activation, of 135- and 100-fold, with BPV1
and HPV16 E2, respectively, from the nonreplicating reporter
compared to basal reporter activity (Fig. 1). When an episomal
reporter was used, moderate activations of 19- and 15-fold for
BPV-1 and HPV-16 E2, respectively, were observed. In SW13
cells, although the activation by the E2 proteins was not as
dramatic as in the C33A cell line, we observed a twofold
increase in the ratio of activity for nonreplicating reporter
compared to the episomal reporter (Fig. 1).
In contrast, the inverse was found in HeLa cells. Transcrip-
tional activation was more robust, at 57- and 88-fold for BPV1
and HPV-16, respectively, detected from the episomal reporter
compared to 7- and 10-fold with a nonreplicating reporter,
respectively (Fig. 1). In NIH 3T3 cells, E2 activation was also
more pronounced with the episomal reporter than with non-
replicating reporter. Similarly, the SWI/SNF-positive, HPV-
negative cell lines PC3 and H1299 also showed higher tran-
scriptional activity with the episomal reporter than with the
nonreplicating reporter (data not shown). In these experi-
ments, equimolar amounts of episomal or nonreplicating plas-
mids were transfected into the cells, with the total amount of
DNA held constant by carrier DNA. Cells were harvested at
24 h posttransfection to limit amplification of the replicating
episomal reporter. Using PCR to detect the luciferase gene in
Hirt extracts from the transfected cells, we found that compa-
rable levels of both reporters were present (data not shown).
We also assayed up to 72 h posttransfection, with results sim-
ilar to the activities at 24 h, although there was slight decrease
in induction in both episomal and nonreplicating reporters
(data not shown), which may be due to progressive loss of the
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E2 expression plasmid. These results suggest that E2 activates
transcription from a chromatin context in an episomal system
and that this activation is enhanced by the presence of the
endogenous SWI/SNF complexes.
Human Brm enhances the transcriptional activity of E2.
Robust transactivation of the episomal reporter compared to a
nonreplicating reporter in HeLa cells and the opposite effect in
C33A cells led us to predict that chromatin remodeling factors
might act as cofactors in transcriptional activation by E2. If this
were the case, E2 transcriptional activity might be enhanced in
a Brm/Brg1-deficient cell line upon heterologous expression of
a SWI/SNF factor such as Brm. To test this, SWI/SNF-defi-
cient C33A cells were transiently transfected with the episomal
reporter plasmid, BPV1 E2, and human Brm. In this cell line,
Brm enhanced E2-mediated activation by 2.7- to 3.7-fold as a
function of increasing amounts of transfected Brm (Fig. 2,
top). The transactivation-defective mutant BPV1 E39G failed
to show any activity itself or in the presence of Brm. A similar
stimulatory response was observed in the Brm/Brg1-deficient
cell line SW13; E2 transcriptional activity increased from 2- to
5.5-fold in SW13 cells with increasing amounts of transfected
Brm (Fig. 2, bottom). To confirm that the transcriptional in-
crease observed was not due to an increase in E2 transcript
levels upon introduction of Brm, we assayed E2 RNA levels by
reverse transcription-PCR. We did not observe any significant
change in the levels of E2 transcripts (data not shown), which
is in agreement with our previous results that the Brm protein
does not significantly alter transcription from a nonreplicating
plasmid (E2 is expressed from the CMV promoter). These
data suggest that enhancement of E2 transactivation is facili-
tated by SWI/SNF factors.
E2 interacts with the Brm complex. We reasoned that for
enhanced transcriptional activation, E2 might physically inter-
act with the Brm complex in vivo. Our attempts to create a
stable cell line expressing wild-type Brm were unsuccessful, as
overexpression of Brm proved to be lethal to SWI/SNF-defi-
cient SW13 cells. This difficulty was overcome by creating a
stable SW13 cell line expressing a Brm protein containing a
C-terminal Flag epitope and a mutation (K804R) in the
ATPase domain. The stable SW13 cells (Brm NTP-Flag) were
transfected with BPV1 E2 and harvested after 24 h. The Brm
complexes were immunoprecipitated with anti-Flag monoclo-
nal antibody, and the bound proteins were analyzed for the
presence of E2 by resolving the precipitates by SDS-PAGE and
subsequent Western analysis using E2 antibodies. The immu-
noblotting results showed that E2 associated with the Brm
complex (Fig. 3a). This interaction is specific, as control anti-
bodies did not coprecipitate the E2 protein.
Brm is a 180-kDa protein, and we had difficulties expressing
it at detectable levels in transient transfection experiments.
This was overcome by introducing a Kozak sequence at the
translation initiation site of the Brm expression vector. This
modified Flag-tagged Brm plasmid was introduced into C33A
cells along with an E2 expression construct. E2 was immuno-
precipitated with rabbit antiserum to E2, and the immunopre-
cipitate was resolved by SDS-PAGE and then immunoblotted
with Flag antibody. The results show that E2 is in complex with
Brm (Fig. 3c). Our unrelated control antibody did not coim-
FIG. 1. Papillomavirus E2 activates transcription in an episomal context. (Top) E2 binding site pREP4-based episomal and pGL2-based
nonreplicating vectors with luciferase reporter gene. (Bottom) HPV-16 (HPV) or BPV1 (BPV) E2 and nonreplicating (NR) or episomal (Ep)
reporters were transfected into C33A, SW13, HeLa, or NIH 3T3 cells. Luciferase activity was normalized to 20 g of total protein. Each experiment
was performed in duplicate and repeated three times.
VOL. 81, 2007 PAPILLOMAVIRUS E2 AND HUMAN Brahma 2215
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munoprecipitate the Brm complex, indicating that the E2-Brm
immunoprecipitation is specific.
To test whether endogenous Brm complexes with E2, we
used HeLa cells that constitutively express high levels of Brm
in coimmunoprecipitation-Western blot experiments. HeLa
cells were transfected with BPV-1 E2 and the Brm-E2 com-
plexes were harvested 24 h posttransfection to avoid senes-
cence due to the repression of E6/E7 transcription (25). Lysates
were immunoprecipitated with a Brm monoclonal antibody and
subjected to Western analysis for E2. Our results indicate that
endogenous Brm associates with the BPV E2 protein and that this
interaction is specific, as the control antibody did not immuno-
precipitate E2 (Fig. 3b).
E2 associates with the Brm complex through its N-terminal
domain. Having demonstrated that E2 associates with the Brm
complex, we proceeded to identify the domain of E2 required
for this interaction. C33A cells were cotransfected with Flag-
tagged Brm and either with full-length BPV E2 or a series of
E2 deletion constructs (6, 89) (Fig. 4a). Cell lysates were sub-
jected to immunoprecipitation with M2 beads to capture the
Brm complexes and immunoblotted with E2 antibodies. Brm
complexed with full-length E2, E2-TAD (1 to 216), and E2-
hinge constructs containing the transactivation domain of E2;
however, it did not associate with E2R (160 to 410), E2 (55 to
410), or E2 (113 to 410) (Fig. 4a and b). These results imply
that the E2-TAD is required for interaction with the Brm
complex.
Increased E2 recruitment to E2 binding sequence by Brm.
Our coimmunoprecipitation experiments demonstrate that E2
physically interacts with the Brm complex, and the reporter
assays show that E2 enhanced transcription from episomal
FIG. 2. Enhanced transactivation by E2 requires hBrm. Episomal
E2 binding site reporter was cotransfected with either BPV1 E2 or
Brm alone and E2 along with increasing amounts of hBrm (0.5, 1, and
1.5 g) into the SWI/SNF-deficient cell lines C33A and SW13. Cells
were harvested and assayed for luciferase activity and normalized to 20
g of total protein.
FIG. 3. E2 associates with the Brm complex in vivo. (a) SW13 cells
stably expressing Flag-tagged ATPase mutant Brm were transfected
with BPV1 E2. The cell extract was immunoprecipitated with anti-Flag
M2 beads or mouse immunoglobulin G (IgG), resolved by SDS-
PAGE, and immunoblotted with E2 antibodies. (b) HeLa cells were
transfected with E2 plasmid, the cell extract was immunoprecipitated
with Brm or control mouse antibodies, and the immunoblot was re-
acted with E2 antibodies. (c) C33A cells were transfected with Flag-
hBrm and E2, the cell extract was immunoprecipitated with rabbit E2
or control antibodies, complexes were resolved by SDS-PAGE, and the
blot was probed with anti-Flag M2 antibodies.
FIG. 4. E2 association with the Brm complex requires the E2 N-
terminal activation domain. (a) Diagram of BPV1 E2 deletion con-
structs. (b and c) Lysates from C33A cells cotransfected with hBrm and
the series of E2 deletion expression vectors were subjected to immu-
noprecipitation (IP) with anti-Flag M2 beads, and the bound com-
plexes were probed with E2 antiserum by immunoblotting.
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promoters. To address whether Brm increases the occupancy
of E2 onto its cognate binding sequences on this episomal
promoter, we performed ChIP assays with SW13 cells. Only
trace levels of the 300-bp region of the episomal reporter
encompassing the four E2 binding sites were amplified follow-
ing ChIP assay with E2 antibodies (Fig. 5a, top). When both E2
and Brm were cotransfected into SW13 cells, there was in-
creased E2-bound reporter DNA detected by PCR (Fig. 5a,
bottom). To confirm the enhanced recruitment of E2 in the
presence of Brm on E2 binding sites, we performed PCR with
increasing volumes of input and immunoprecipitated DNA
(Fig. 5b; compare the top and bottom panels). To test whether
Brm-enhanced E2 recruitment to E2 binding sites requires the
adjacent promoter and associated transcription factors, we
performed ChIP assays using an episomal plasmid containing
E2 binding sites but without the promoter region. Our results
show that exogenous Brm increased the loading of E2 onto E2
binding sites (Fig. 5c and d). These results demonstrate that
Brm facilitates E2 occupancy on its cognate binding sites.
DISCUSSION
Viral transcription is programmed by E2 binding sequences
and multiple regulatory elements present in the LCR. Tran-
scription of the early LCR promoter is repressed by heterolo-
gous expression of E2, but the contribution of E2 transcrip-
tional activation in the context of the genome has not been
fully evaluated. While the transcriptional activation property of
E2 is highly conserved (36, 80), this is typically studied by transient
transfection of a nonreplicating E2-dependent reporter. One
function of E2 proposed to be necessary for activation of tran-
scription and replication is relief of nucleosome-mediated re-
pression (42, 43, 88). Therefore, to address whether E2 can
activate or repress transcription in the context of episomes,
independent of secondary effects on PV protein expression and
viral genome replication, we undertook a conventional ap-
proach in which E2 binding sites were positioned upstream of
a minimal promoter and introduced into an EBV-based epi-
somal luciferase reporter. EBV-based episomal luciferase re-
porter systems have been exploited to address the role of
chromatin remodeling factors in transcription. These studies
have shown that to assess the transcriptional activity of SWI/
SNF remodeling factors, an episomal reporter system is more
suitable than a nonreplicating reporter (17, 29, 46, 48, 84, 87).
Using this assay system, we show that the BPV1 and HPV-16
E2 proteins activate transcription from an episomal promoter.
This activation is enhanced in cells in which chromatin remod-
eling enzymes are abundant and is correspondingly reduced in
those that are deficient.
Interestingly, with an episomal reporter system, E2 tran-
scriptional activity increased relative to a nonreplicating re-
porter in the cell lines that express SWI/SNF factors. In HeLa
cells, E2 showed robust activation with an episomal reporter
compared to a nonreplicating reporter. HeLa cells have been
extensively used to purify and characterize the components of
SWI/SNF remodeling complexes (37, 38, 57, 70, 71, 83). In
contrast, E2 showed weaker transcriptional activity on an ep-
isomal reporter than on a nonreplicating reporter in C33A
cells. Correspondingly, C33A cells do not express detectable
levels of Brm/Brg1 (54). We also observed a similar pattern of
reduced activity with an episomal reporter compared to a non-
replicating reporter in SW13 cells. SW13 is commonly used as
a SWI/SNF-deficient cell line (18, 46, 48). Importantly, heter-
ologous expression of Brm enhanced the transcriptional activ-
ity of E2 from the episomal reporters in C33A and SW13 cells.
We also observed relatively higher transcriptional activity of
E2 on an episomal reporter than on a nonreplicating reporter
in other SWI/SNF-positive cell lines, such as PC3 and H1299
(data not shown). A recent report indicated that the HPV-16
E2 protein is unable to activate transcription from an episomal
HPV-16 genome present in the established cell line W12 (2).
This outcome may also be complicated by the physiologic reg-
ulation of HPV E6 and E7, on which the cells depend for
viability.
We show that E2 interacts with endogenous human Brm
expressed in HeLa cells and Brm K804R expressed stably in
FIG. 5. Brm increases the loading of E2 on E2 DNA binding sites.
(a) The episomal reporter containing E2 binding sites was introduced
into SW13 cells together with E2 alone or E2 plus hBrm. Formalde-
hyde was directly added to the medium at 24 h after transfection, and
chromatin extract was subjected to E2 ChIP assay. (b) PCR was per-
formed with increasing volumes (0.5 to 2 l) of chromatin extracts for
E2 ChIP assays, as described for panel a. (c) As in panel a, cotrans-
fection of the episomal vector containing E2 binding sites but without
the adjacent promoter sequences along with E2, in the presence or
absence of exogenous hBrm, and subjected to E2 ChIP assay. (d) PCR
was performed with increasing volumes (0.5 to 2 l) of chromatin
extracts and E2 ChIP assays, as described for panel c. Cont, control; IP,
immunoprecipitation.
VOL. 81, 2007 PAPILLOMAVIRUS E2 AND HUMAN Brahma 2217
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SW13 cells. BPV and HPV E2 transcriptional activation cor-
relates with levels of the Brm factor in transiently transfected
Brg1/Brm-deficient cells. Our mapping results showed that the
E2 amino-terminal TAD region is required for interaction with
the Brm complex. It remains to be determined whether the
association of E2 with Brm is direct or mediated by other
factors. Brm interaction mapped to a large region of the E2
TAD, suggesting that multiple contacts and factors may be
necessary for assembly of a stable Brm SWI/SNF complex. The
E2 binding proteins Gps2 and hNAP-1 interact with p300 and
probably connect E2 to this histone acetylase to modify chro-
matin access (7, 58, 65). TopBP1 is another candidate factor
that may bridge E2 and Brm, as it interacts with the SWI/SNF
remodeling complex (4, 47).
Viral proteins are known to interact with chromatin-modi-
fying factors or remodeling complexes (45). HPV E7 interacts
with the chromatin remodeling factor Brg1 and deregulates the
transcriptional properties of Brg1 (40). Likewise, several viral
proteins, such as the human immunodeficiency virus type 1
integrase, Tat, Tax, EBNA2, E1A, and SV40 large T protein,
interact with chromatin-modifying factors in modulating their
transcriptional properties (21–23, 50, 86, 90). Our coimmuno-
precipitation results extend this list to papillomavirus E2. In-
terestingly, HPV E1 protein has been reported to directly
interact with the nucleosomal protein H1 (76) and with the
SWI/SNF chromatin remodeling component Ini1 (41). An E1
mutant defective for Ini1 binding failed to support replication
of the viral genome. These observations suggest that E1 en-
gages these enzymes during S phase to drive viral episome
replication. E2 may also have a role in replication, as it was
shown that E2 opposes the nucleosomal repression of the viral
genome and facilitates its replication in vitro (42). Interest-
ingly, E2 binding sites and additional elements that extend
beyond the minimal replication origin that is otherwise suffi-
cient for transient DNA replication are necessary for BPV
genome maintenance (30). In an elegant study that investi-
gated chromatin structure, nucleosome rearrangement was ob-
served on the HPV-31 genome during epithelial cell differen-
tiation and late gene expression was induced with histone
deacetylase inhibitor (12).
SWI/SNF enzymes are proposed to disrupt histone-DNA
contacts such that the histone octamer slides along the DNA,
thereby mobilizing and repositioning the nucleosomes (33, 85).
Although the precise mechanism by which SWI/SNF com-
plexes disrupt nucleosome structure is still not fully resolved,
recent data support the notion that these remodeling enzymes
act as DNA translocating motors (67). Remodeling activity
leads to enhanced accessibility of nucleosomal DNA to se-
quence-specific DNA binding proteins and facilitates numer-
ous aspects of development, differentiation, cell cycle control,
signaling, and transcriptional regulation (10, 11, 32, 38, 49, 66,
67, 81).
Numerous studies have shown that transcription factors re-
cruit the SWI/SNF complex to promoter regions during tran-
scriptional activation (8, 11, 34, 68). By ChIP assays, we show
that Brm increases promoter occupancy by E2 on a chromatin
template. These results suggest that E2 exploits the cellular
Brm complex for its transcriptional activity. Moreover, our
ChIP assays suggest that Brm enhances the occupancy of E2 on
its binding sites in the absence of the minimal promoter. We do
not know at this point whether the accessibility or stability of
E2 protein is increased at the site of transcription by interac-
tion with the SWI/SNF complex. Overall, our findings are in
agreement with published reports and with the prediction that
nucleosomes on the viral genome pose an obstacle to the
transcription and replication machinery, an obstacle which is
overcome by recruitment of the SWI/SNF complex by E2.
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